Elimination of canrenone in congestive heart failure and chronic liver disease

@article{Jackson1977EliminationOC,
  title={Elimination of canrenone in congestive heart failure and chronic liver disease},
  author={Lazette Jackson and R D Branch and Danielle L Levine and Lawrence E Ramsay},
  journal={European Journal of Clinical Pharmacology},
  year={1977},
  volume={11},
  pages={177-179}
}
The elimination half-life (T1/2) of canrenone, the principal unconjugated metabolite of spironolactone, was 59 h (range 32–105 h) in 5 patients with chronic liver disease and 37 h (range 19–48 h) in 7 patients with congestive heart failure. In comparison the T1/2 in normal subjects was 13.5–24 h in previous reports and 20.5 h in the present study. However there was no evidence of greater cumulation of canrenone in the plasma of those patients with a prolonged T1/2. 

From This Paper

Topics from this paper.
2 Citations
8 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-8 of 8 references

Aldosterone and aldosteronism

  • E. J. Ross
  • LloydLuke
  • 1975

Pharmacokinetics of Aldactone in humans

  • W Sadee, M. Dagcioglu
  • Extrarenal activity of aldosterone and its…
  • 1972

Schr6der, R.:Pharmacokinetics of Aldactone in humans

  • W Sadee, M. Dagcioglu
  • 1972
1 Excerpt

Similar Papers

Loading similar papers…